Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

Abstract Background These subgroup analyses of a Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of erenumab 70 mg in Japanese migraine patients with/without prior preventive treatment failure(s) (“failed-yes” and “failed-no” subgroups) and with/without...

Full description

Bibliographic Details
Main Authors: Koichi Hirata, Fumihiko Sakai, Takao Takeshima, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Yotaro Numachi, Cheng Peng, Daniel D. Mikol, Sunfa Cheng
Format: Article
Language:English
Published: BMC 2021-09-01
Series:The Journal of Headache and Pain
Subjects:
Concomitant preventive treatment
Erenumab
Migraine
Prior preventive treatment failure
Online Access:https://doi.org/10.1186/s10194-021-01313-8

Internet

https://doi.org/10.1186/s10194-021-01313-8

Similar Items